Appendix 4E and 2019 Annual Report
Filed with ASX · · 55 pages · English
$ Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Group after providing for income tax amounted to $411,326 (30 June 2018: $2,497,252). During the period, the Group had total revenue of $844,365 (2018: $520,525), consisting of the R&D tax incentive of $644,298 (2018: $455,207), licencing income of $27,500 (2018: $27,500
Story so far
Earlier from Patrys
- Appendix 4C - Quarterly - 30 June 2019
- PAT-DX1 significantly improves survival in aggressive GBM
- Europe grants patent for Deoxymab 3E10
- PAT-DX1 Reduces Brain Metastases, Enhances Radiation Therapy
- Appendix 4C - Quarterly - 31 March 2019
Later from Patrys
- Appendix 4C - Quarterly - 30 September 2019
- Appendix 4C - Quarterly - 31 December 2019
- Appendix 4D - Half Year Accounts - 31 December 2019
- PAT-DX1-NP crosses BBB and targets tumours
- PAT-DX1 mechanism for crossing blood brain barrier confirmed
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys